Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 + toripalimab plus chemotherapy vs toripalimab plus chemotherapy vs chemotherapy alone as neoadjuvant therapy for stage II–III TNBC
ChiCTR2500108554Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tifcemalimab and toripalimab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: pathological complete response (pCR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tifcemalimabtoripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2500108554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108554.